Growing evidence suggests that PTGER3, another subtype of prostaglandin E receptors, exhibits differential expression in various cancers, such as cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where its lower expression correlates with poor prognosis and recurrence-free survival [12]. Here, PTGER3 is linked to cancer.